SEARCH

SEARCH BY CITATION

References

  • Attarbaschi, A., Morak, M., Cario, G., Cazzaniga, G., Ensor, H.M., te Kronnie, T., Bradtke, J., Mann, G., Vendramini, E., Palmi, C., Schwab, C., Russell, L.J., Schrappe, M., Conter, V., Mitchell, C.D., Strehl, S., Zimmermann, M., Potschger, U., Harrison, C.J., Stanulla, M., Panzer-Grumayer, R., Haas, O.A. & Moorman, A.V., on behalf of the AIEOP-BFM Study Group and NCRI-CCLG Study Group. (2012) Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. British Journal of Haematology, 158, 772777.
  • Cario, G., Zimmermann, M., Romey, R., Gesk, S., Vater, I., Harbott, J., Schrauder, A., Moericke, A., Izraeli, S., Akasaka, T., Dyer, M.J., Siebert, R., Schrappe, M. & Stanulla, M. (2010) Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood, 115, 53935397.
  • Chen, I.M., Harvey, R.C., Mullighan, C.G., Gastier-Foster, J., Wharton, W., Kang, H., Borowitz, M.J., Camitta, B.M., Carroll, A.J., Devidas, M., Pullen, D.J., Payne-Turner, D., Tasian, S.K., Reshmi, S., Cottrell, C.E., Reaman, G.H., Bowman, W.P., Carroll, W.L., Loh, M.L., Winick, N.J., Hunger, S.P. & Willman, C.L. (2012) Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood, 119, 35123522.
  • Ensor, H.M., Schwab, C., Russell, L.J., Richards, S.M., Morrison, H., Masic, D., Jones, L., Kinsey, S.E., Vora, A.J., Mitchell, C.D., Harrison, C.J. & Moorman, A.V. (2011) Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood, 117, 21292136.
  • Harvey, R.C., Mullighan, C.G., Chen, I.M., Wharton, W., Mikhail, F.M., Carroll, A.J., Kang, H., Liu, W., Dobbin, K.K., Smith, M.A., Carroll, W.L., Devidas, M., Bowman, W.P., Camiitta, B.M., Reaman, G.H., Hunger, S.P., Downing, J.R. & Willman, C.L. (2010) Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood, 115, 53125321.
  • Haslam, K., Kelly, J., Morris, T., Connaghan, G., Gilligan, O., Browne, P. & Langabeer, S.E. (2011) Screening for CRLF2 overexpression in adult acute lymphoblastic leukemia. International Journal of Laboratory Hematology, 33, e17e19.
  • Mullighan, C.G., Collins-Uderwood, J.R., Phillips, L.A., Loudin, M.G., Liu, W., Zhang, J., Ma, J., Coustan-Smith, E., Harvey, R.C., Willman, C.L., Mikhail, F.M., Meyer, J., Carroll, A.J., Williams, R.T., Cheng, J., Heerema, N.A., Basso, G., Pession, A., Pui, C.-H., Raimondi, S.C., Hunger, S.P., Downing, J.R., Carroll, W.L. & Rabin, K.R. (2009) Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nature Genetics, 41, 12431246.
  • Palmi, C., Vendramini, E., Silvestri, D., Longinotti, G., Frison, D., Cario, G., Shochat, C., Stanulla, M., Rossi, V., Di Meglio, A.M., Villa, T., Giarin, E., Fazio, G., Leszl, A., Schrappe, M., Basso, G., Biondi, A., Izraeli, S., Conter, V., Valesecchi, M.G., Cazzaniga, G. & Te Kronnie, G. (2012) Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia, 26, 22452253.
  • Russell, L.J., Capasso, M., Vater, I., Akasaka, T., Bernard, O.A., Calasanz, M.J., Chandrasekaran, T., Chapiro, E., Gesk, S., Griffiths, M., Guttery, D.S., Haferlach, C., Harder, L., Heidenreich, O., Irving, J., Kearney, L., Nguyen-Khac, F., Machado, L., Minto, L., Majid, A., Moorman, A.V., Rand, V., Strefford, J.C., Schwab, C., Tonnies, H., Dyer, M.J., Siebert, R. & Harrison, C. (2009) Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood, 114, 26882698.
  • Tasian, S.K., Doral, M.Y., Borowitz, M.J., Wood, B.L., Chen, I.-M., Harvey, R.C., Gastier-Foster, J.M., Willman, C.L., Hunger, S.P., Mullighan, C.G. & Loh, M.L. (2012) Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood, 120, 833842.